Medartis Raises Full-Year 2026 Growth Forecast Driven by US Performance

Medartis raised its 2026 growth outlook, saying organic core revenue growth at constant exchange rates is likely to exceed its previous guidance of 17%–19%, while its core EBITDA margin is expected to reach the upper end of the high-teens range. Strong US performance is driving the revision, including more than 2,000 procedures using its Touch thumb saddle joint prosthesis by the end of October; Medartis now expects about 3,000 procedures for the full year, up from its August forecast of 1,800. The company also reported continued positive development in endoprosthetics and osteosynthesis, particularly in EMEA.